Zymergen (NASDAQ:ZY) and Medpace (NASDAQ:MEDP) Financial Comparison

Medpace (NASDAQ:MEDP) and Zymergen (NASDAQ:ZY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Medpace and Zymergen, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medpace 0 0 3 0 3.00
Zymergen 4 4 0 0 1.50

Medpace presently has a consensus price target of $190.97, suggesting a potential downside of 10.35%. Zymergen has a consensus price target of $9.83, suggesting a potential downside of 1.67%. Given Zymergen’s higher probable upside, analysts clearly believe Zymergen is more favorable than Medpace.


This table compares Medpace and Zymergen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Medpace 17.07% 21.74% 12.82%
Zymergen N/A N/A N/A

Valuation & Earnings

This table compares Medpace and Zymergen’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medpace $925.92 million 8.24 $145.38 million $4.00 53.26
Zymergen N/A N/A N/A N/A N/A

Medpace has higher revenue and earnings than Zymergen.

Insider and Institutional Ownership

76.3% of Medpace shares are owned by institutional investors. Comparatively, 51.0% of Zymergen shares are owned by institutional investors. 22.0% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


Medpace beats Zymergen on 8 of the 9 factors compared between the two stocks.

Medpace Company Profile

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Zymergen Company Profile

Zymergen Inc. designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe. The company has a platform that treats the genome as a search space, to identify genetic changes that improve the economics for its customers' bio-based products for a range of industries, including chemicals and materials, agriculture, and pharmaceuticals. Zymergen's platform is used to discover novel molecules used to enable unique material properties. The company was incorporated in 2013 and is based in Emeryville, California.

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.